Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation – Regeneron

1. Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation  Regeneron
2. Understanding Second Primary Tumors in C-POST: Definitions, Incidence, and Clinical Implications of Cemiplimab  Pharmacy Times
3. Regeneron (REGN) EC Approves Libtayo as First Adjuvant CSCC Immunotherapy, 68% Risk Cut  Stock Titan

Continue Reading